Educating Patients About the Need to Wait for Biomarker Test Results

Video Library —June 8, 2021
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)
Thoracic Oncology Nurse Navigator
University of Chicago Medicine
Chicago, Illinois
Cathy Simmons, RN, BSN, ONN-CG(T)
Thoracic Oncology Navigator
Sarah Cannon Cancer Institute
Plano, Texas
Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, Kammi Fox-Kay, and Cathy Simmons discuss their approaches to educating patients on the importance of waiting for biomarker testing before starting therapy for non–small cell lung cancer (NSCLC) to individualize therapy with the treatment that is best suited for their cancer and to achieve the best outcomes.
Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country